Andrew J. Stott

Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease

Roland W. Bürli, Christopher A. Luckhurst, Omar Aziz et al. · Journal of Medicinal Chemistry · 2013 · 149 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors

Christopher A. Luckhurst, Perla Breccia, Andrew J. Stott et al. · ACS Medicinal Chemistry Letters · 2015 · 55 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

An Immunological Analysis of Ty1 Virus-like Particle Structure

Jayne L. Brookman, Andrew J. Stott, Philip J. Cheeseman et al. · Virology · 1995 · 47 citations

Life Sciences, Immunology, Molecular Biology +12

Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor

Christopher A. Luckhurst, Omar Aziz, Vahri Beaumont et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 46 citations

Medicine, Medicinal Chemistry, Pharmacology +9

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease

Andrew J. Stott, Michel Maillard, Vahri Beaumont et al. · ACS Medicinal Chemistry Letters · 2021 · 45 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16